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Prevalence and factors associated with  
cutaneous manifestations of type 2  
diabetes mellitus 
ABSTrACT
Background. Type 2 diabetes mellitus (T2DM) is known 
to cause multiple systemic manifestations. however, 
there are limited studies describing cutaneous manifes-
tation among T2DM in Malaysia. The objective of this 
study was to determine the prevalence of cutaneous 
manifestation among T2DM patients, types of lesions 
and its associated factors. 
Methods. A cross-sectional study was conducted 
among 271 T2DM patients at a primary care clinic in 
Kuala lumpur. 
results. More than one third (63.5%) of patients were 
found to have cutaneous manifestations of T2DM. The 
most common manifestation was infections (34.7%) 
followed by Skin Diseases with Weak to Strong Associa-
tion with Diabetes (SDWSAD) (31.7%), Skin Manifesta-
tion of Diabetic Complication (SMDC) (2.2%) and oth-
ers cutaneous lesions (22.1%). Among the infections, 
onychomycosis was the commonest type of infection 
(27.7%) while diabetic dermopathy was the common-
est lesion of SDWSAD (29.7%). Males had almost two 
times the odds of developing cutaneous manifesta-
tions of T2DM, compared to females (adjusted odds 
ratio [AOr]: 1.871, 95% CI: 1.108–3.160; P = 0.019). 
There was no association between glycemic control 
and cutaneous manifestations. however, males and 
those with T2DM duration of five years and more had 
2.6 times the odds of developing SDWSAD (AOr: 2.646, 
95% CI: 1.506–4.648 P = 0.001) and (AOr: 2.635, 95% 
CI: 1.107–6.268, P = 0.028) respectively. Those with 
diabetic neuropathy and peripheral vascular disease 
(PVD) had very high odds of developing SMDC such 
as diabetic foot and trophic ulcers (AOr: 23.259, 95% 
CI: 1.191–454.2, P = 0.038) and (AOr: 102.36, 95% CI: 
4.013–2610, P = 0.005), respectively. 
Conclusion. The knowledge of these cutaneous 
manifestations increases physician’s awareness and 
prompts early screening to reduce morbidity improve 
quality of life. (Clin Diabetol 2020; 9; 6: 461–468)
Key word: diabetes mellitus, skin manifestations, 
glycated hemoglobin A, prevalence 
Introduction 
South-East Asia accounts for more than 60% of the 
world’s diabetes population [1]. The rapid rise in type 2 
diabetes mellitus (T2DM) prevalence in Malaysia is 
alarming with 70 to 80% of patients having poor gly-
cemic control [2]. Cutaneous manifestations of diabetes 
mellitus appear at disease onset, after the disease is 
established or precede diabetes by many years. A cu-
taneous condition is defined as any medical condition 
that affects the system enclosing the body, including 
the skin, hair, nails, and related muscle and glands [3]. 
Cutaneous disorders due to T2DM are attributed to 
hyperglycemia which affects skin homeostasis resulting 
in altered keratinocytes metabolism and collagen pro-
perties [4, 5]. Relative insulin deficiency in T2DM causes 
poor growth and differentiation of keratinocyte [4, 5]. 
Certain conditions such as skin tags and acanthosis nig-
ricans are linked to hyperinsulinemia in the prediabetic 
state while bullous diabeticorum, diabetic dermopathy 
and scleroderma are more often see in long stand-
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ing T2DM [6]. Microvascular complications, impaired 
wound healing and other undetermined mechanisms 
further contribute to cutaneous disease [7].
Prevalence of dermatological disorders due to 
T2DM ranges from 36% to as high as 88.3% [8, 9]. 
Factors associated with cutaneous manifestations 
are poor glycemic control (HbA1c > 7%) [10, 11] and 
duration of diabetes [8]. Longer disease duration have 
higher incidence of diabetic dermopathy [8]. Profiling 
characteristics of T2DM and cutaneous manifesta-
tions may help in early diagnosis of diabetes, used 
as a surrogate marker for poor glycemic control and 
microvascular complications in other organs. Hence 
the aim of this study is to determine the prevalence of 
cutaneous manifestation among patients with T2DM 
and to determine its associated factors. 
Methods
A cross-sectional study was performed between 
June and September 2019 at the primary care clinic of 
a university in Kuala Lumpur. Sample size of 246 was 
calculated using Kish formula, 80% was taken as the 
highest prevalence cutaneous manifestation of T2DM 
[8] with 95% confidence interval and 5% absolute 
precision. The final sample size was 271 as 10% was 
added to overcome possible incomplete data. Partici-
pants were selected using systematic random sampling 
(sampling interval of 2) from the list of T2DM patients 
who registered for consultation. Type 1 diabetes mel-
litus (T1DM), pregnancy and patients with dermatoses 
due to physical factors such as burns, and trauma were 
excluded. Written consent was obtained. A thorough 
physical examination from head to toe including 
genitalia was performed to evaluate the cutaneous 
manifestations.
A data collection form was designed to record the 
intended data, based on a literature search and expert 
opinion. Section A consists of socio-demographic in-
formation such as age, gender, ethnicity and clinical 
profile such as duration of diabetes, diabetic compli-
cation (neuropathy, nephropathy, retinopathy, and 
peripheral vascular disease), body mass index (BMI) and 
HbA1c level. Information on HbA1c, diabetic retinopa-
thy, nephropathy and lipid levels was extracted from 
participant’s electronic database. For the purpose of 
this study, HbA1c level of > 6.5% was considered as 
poor glycemic control while ≤ 6.5% was considered as 
a good glycemic control [12]. Peripheral neuropathy 
was screened using 10-g monofilament, vibration 
sense using a 128-Hz tuning fork and ankle reflex [12]. 
Peripheral vascular disease (PVD) was objectively 
screened based on examination of distal pulses, capil-
lary return time and skin color. 
Section B recorded cutaneous manifestation of 
T2DM that was diagnosed on the consultation day. A 
list of skin manifestations associated with T2DM was 
derived from literature search and expert panel input 
[13, 14]. Cutaneous manifestations of diabetes mellitus 
were classified into 4 types which are skin diseases with 
weak to strong associations with diabetes (SDWSAD), 
skin infections (SI), skin manifestations due to diabe-
tes complication (SMDC) and skin reaction to diabetic 
treatment [13, 14]. Skin reaction to diabetic treatment 
was excluded as the objective of this study was to 
determine the cutaneous manifestations purely due 
to T2DM and not due to effect of treatment or other 
secondary causes. Hence lesions which fulfilled these 
three categories were included: 
 — Skin Diseases with Weak to Strong Associations 
with Diabetes (SDWSAD): diabetic dermopathy, 
acanthosis nigricans, yellow skin, eruptive xan-
thoma, oral leukoplakia, lichen planus, necrobiosis 
lipoidica, granuloma annulare and diabetic bullae. 
Diabetic dermopathy is described as asymptomatic 
well circumscribed pinkish or brownish atrophic 
(depressed) lesion on shin, thigh, forearm, scalp or 
trunk. Lesion may arise in crops gradually resolve, 
reappear and sometimes ulcerate;
 — Skin infections (SI): impetigo, ecthyma, cellulitis, 
folliculitis, furunculosis, carbuncles, erysipelas, vi-
ral warts, tinea capitis, tinea pedis, tinea corporis, 
tinea cruris, tinea versicolor, tinea manuum, paro-
nychia, onychomycosis, candidiasis. Infections 
of both dermal and mucosa surfaces were taken 
into consideration encompassing all types of bac-
terial and viral infections. All four clinical types 
of onychomycosis i.e. total dystrophic, white su-
perficial, candida, proximal and distal subungual 
onychomycosis were all included under the broad 
term of onychomycosis;
 — Skin manifestation of diabetic complication 
(SMDC): microangiopathy, macroangiopathy, 
neuropathy e.g. diabetic foot and trophic ulcers.
Patients presenting with of any of the cutaneous 
disorders related to T2DM was labelled as having cu-
taneous manifestations of T2DM. Other cutaneous le-
sions were recorded if found to be present. The primary 
researcher received hands-on training from a qualified 
dermatologist and a family medicine specialist with 
qualification in family practice dermatology prior to 
the commencement of this study. Clinical diagnosis was 
made by the primary investigator. Inter-rater reliability 
for the clinical diagnosis between the 3 investigators 
was performed using images of the lesions and meas-
ured using Cohen’s Kappa to ensure the reliability of 
the diagnosis.
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The data collected was analyzed using SPSS (ver-
sion 25). Descriptive analysis was performed using 
frequencies and percentage. Simple and multiple lo-
gistic regression analyses were used to determine the 
association between type of cutaneous manifestation 
with sociodemographic characteristics and clinical 
profile. Cohen’s Kappa was used to determine the 
agreement between the researchers’ diagnoses of the 
skin condition. This research was approved by the Re-
search and Ethics Committee of University Kebangsaan 
Malaysia Medical Centre (FF-2018-088) and registered 
with the National Medical Research Registry (NMRR-
17-2555-38622).
Results
A total of 271 patients participated in this study. 
The median age was 66 (SD 13) years, ranging from 28 
to 91 years. Almost half of the participants belonged to 
the Malay ethnic group 131 (48.3%) and 128 (47.2%) 
were obese. Female to male ration was almost equal 
(1:1.08). A large majority of participants 223 (82.3%) 
had T2DM for more than 5 years. The median HbA1c 
was 7.7 (2.4) and most 211 (77.9%) had poor glucose 
control (HbA1c >6.5). About half of them 142 (52.4%) 
had diabetes complication with nephropathy being the 
commonest 24 (27.3%) (Table 1).
The interrater agreement between the three in-
vestigators on the clinical diagnosis of the cutaneous 
lesions was good with a Cohen’s Kappa value 0.91 (95% 
confidence interval). More than half of the participants 
(58.2%) presented with one type of lesion while the rest 
had two or more types of lesions. The prevalence of 
cutaneous disorders related to T2DM was 172 (63.5%) 
with infections being the commonest presentation 94 
(34.7%). Fungal infection was commonest (39.9%) 
(Fig. 1A–E) presenting as onychomycosis (27.7%) (Fig. 
1A–C). The most common SDWSADs were diabetic 
dermopathy (29.9%) (Fig. 1F) and necrobiosis lipoidica 
(2.6%). Only 0.4% had acanthosis nigricans (Table 2). 
Other cutaneous lesions observed were eczema 39 
(14.4%) (Fig. 1C, G), xerosis 12 (4.4%) (Fig. 1A, H) and 
callus 5 (1.8%) (Fig. 1I).
Multivariate analysis using independent variables 
with P values of less than 0.25 and variables considered 
clinically important showed significant association 
between cutaneous manifestation and gender. Males 
were almost two times more likely to have cutaneous 
manifestation (1.89 [95%CI; 1.12–3.20], P = 0.02) 
compared to females (Table 3). Males (2.55 [95%CI: 
1.46–4.43]) and those with duration of T2DM of more 
than 5 years (2.42 [95%CI: 1.03–5.70]) have 2 times 
the odds of having SDWSAD (Table 4).
Regression analysis demonstrated significant as-
sociations between skin manifestations with SMDC 
such as diabetic neuropathy (P = 0.038) and peripheral 
vascular disease (P = 0.005). The presence of diabetic 
neuropathy has 23 times the odds of having SMDC 
(95% CI: 1.191–454.20, P = 0.038), while peripheral 
vascular diseases (PVD) 102 times the odds of having 
SMDC (95% CI: 4.013–2610, P = 0.005) (Table 5). 
However, these findings need to be interpreted cau-
tiously in view of small number of cases with SMDC. 
There was no association between skin infection and 
other cutaneous lesions with the sociodemographic 
and clinical profile. 
Table 1. Sociodemographic and clinical characteristics of 
the study participants 
Variables n (%) Median (IQr)








Duration of DM in years 10 (10)
BMI [kg/m²] 27 (6)
hBA1c (%) 7.7 (2.4)
lDl level [mmol/l] 2.4 (1.1)
Duration of DM
< 5 years 48 (17.7)
≥ 5 years 223 (82.3)
Glycemic control
Good control (HbA1c ≤ 6.5%) 60 (22.1)





Overweight (BMI 23–27.4) 103 (38.0)








Peripheral vascular disease 6 (2.2)
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Figure 1. Cutaneous lesion in T2DM: A — amputated little toe with onychomycosis and xerosis; B — onychomycosis with chronic 
paronychia; C — onychomycosis of the big toe due to Aspergillus niger with eczema craquele over the dorsum of the foot; 
D — extensive tinea cruris over the gluteal regions extending to the upper thighs; E — maceration of the interdigital space due 
to fungal infection; F — diabetic dermopathy characterized by multiple discrete, hyperpigmented and atrophic macules and 
patches with thin scales; g — ichthyosis over the lower limb; h — xerosis with generalized thin scales over the lower limb; I — 





Skin manifestations of T2DM vary in different parts 
of the world. An outline of common conditions and 
their etiology would help physicians manage T2DM pa-
tients in a holistic manner. We found a high prevalence 
of cutaneous manifestation of T2DM. The prevalence 
was similar to that in India, Pakistan and Hong Kong 
which is between 58 to 67% [10, 15, 16]. Skin infec-
tion was the most common cutaneous manifestation 
of T2DM in our patients, followed by SDWSAD with 
diabetic dermopathy. Infections and diabetic dermopa-
thy are common cutaneous disorders associated with 
diabetes [8, 15, 16]. Diabetic foot and trophic ulcer 
were the most common manifestations of SMDC. Skin 
infection is common among T2DM patients due to 
lower immunity and defect in carbohydrate metabo-
lism compared to the normal population [17]. Fungal 
infection presenting with onychomycosis was the most 
common pathogen among the infective conditions in 
our patients. The hot and humid local climate environ-
ment is favorable for fungal growth. Fungal infection 
alters skin barrier and predispose to complications such 
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as cellulitis. Fungal infections should be identified early 
and treated. 
We did not determine the onset of lesions in 
relation to diabetes duration. Skin manifestation like 
acanthosis nigricans precede diabetes, screening for 
diabetes at regular intervals for early diagnosis would 
be beneficial [6]. Although acanthosis nigricans is 
popularly described as a common association with 
T2DM, only 0.4 % of our study participants had this 
manifestation. Prevalence acanthosis nigricans ranged 
from 1.88% to 4% [8, 18]. 
We identified the male gender and duration of 
T2DM of ≥ 5 years as risk factors for SDWSA. Diabetic 
dermopathy was significantly more frequent in males 
and those with longer duration of DM [19, 20]. Skin 
lesions were also more common among diabetic men 
[16]. Skin diseases affect men and women differently 
and this is attributed differences in skin thickness, pH, 
effect of sex hormone and immune system [21]. Our 
study did not show an association between BMI and 
risk for cutaneous manifestations of T2DM or SDWSA. 
This may be attributed to the cross-sectional nature of 
this study where at the point of data collection, cuta-
neous signs were not elicited as it may have resolved 
after treatment or yet to manifest in the future, which 
may be identified in a longitudinal study. 
Although an association was expected between 
the presence of cutaneous manifestations of T2DM and 
poor glycemic control, this was not evident in our study. 
There are inconsistent observations on the association 
between cutaneous manifestations of T2DM with gly-
cemic control with some showing positive association 
while some did not show any association [22–24]. The 
cause for cutaneous manifestations of T2DM is mul-
tifactorial and not purely due to hyperglycemia. The 
lack of standardization in the cut off values for good 
and poor glycemic control based on HbA1c in earlier 
studies makes the comparison of outcome difficult. 
HbA1c of more than 6.5% is considered as poor control 
while some consider 7% as poor control. HbA1c test is 
performed 6 monthly for our local diabetic population. 
An average HbA1c level over a longer duration would 
give a better evaluation of control compared to a single 
reading to assess the association. 
As expected, patients with diabetic neuropathy 
and PVD have very high odds of having SMDC, such 
as diabetic foot and trophic ulcers in our study. These 
associations are well described [25, 26]. Peripheral 
vascular disease and diabetic neuropathy are indeed 
risks for developing diabetic foot and trophic ulcers 
due to poor sensation and blood circulation of the 
lower limbs. Diabetic foot ulcer is a strong predictor 
for major limb amputation [27]. Regular foot assess-
Table 2. Prevalence and types of cutaneous manifestations
Variables n (%)
Presence of cutaneous disorders related to T2DM
Yes 172 (63.5)
No 99 (36.5)
Types of cutaneous manifestation
Infections (fungal, bacterial or viral) 94 (34.7)
Skin diseases with weak to strong association 
with diabetes (SDWSAD)
86 (31.7)
Other cutaneous lesions 60 (22.1)
Skin Manifestation of Diabetic Complications 
(SMDC)
6 (2.2)
Types of skin diseases with weak to strong  
association with diabetes 
(SDWSAD)
Diabetic dermopathy 81 (29.9)
Necrobiosis lipoidica 7 (2.6)
Acanthosis nigricans 1 (0.4)







Tinea pedis 8 (3)
Viral wart 6 (2.2)
Candidiasis 5 (1.8)
Tinea corporis 5 (1.8)
Folliculitis 5 (1.8)





Tinea manuum 1 (0.4)
Skin manifestation of diabetic complication
Diabetic foot 6 (2.2)











*The term eczema here is inclusive of both endogenous and exogenous 
types of eczema
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Table 3. risk factors for cutaneous manifestation of T2DM
Variables Crude Or (95% CI) P value Adjusted Or (95% CI) P value
Gender




Non-Malay 0.64 (0.39–1.06) 0.08 0.65 (0.39–1.10 0.10
BMI
Underweight/normal (1) (1)
Overweight 1.07 (0.51–2.25) 0.85 0.86 (0.40–1.87) 0.71
Obese 1.63 (0.78–3.37) 0.19 1.352 (0.63–2.90) 0.44
Duration of DM
< 5 years (1) (1)
≥ 5 years 1.05 (0.55–2.01) 0.88 0.93 (0.47–1.85) 0.84
glycemic control
Good (HbA1c ≤ 6.5%) (1) (1)
Poor (HbA1c > 6.5%) 1.21 (0.67–2.18) 0.53 1.09 (0.58–2.03) 0.79
Diabetic complication
Yes 1.53 (0.93–2.51) 0.10 1.40 (0.82–2.38) 0.22
No (1) (1)
*Indicate significant P < 0.05, (1) ‐ reference group, adjusted for gender, ethnicity, BMI group, duration of DM, glycemic control, nephropathy, retinopathy 
Table 4. risk factors for SDWSAD type of cutaneous manifestation of T2DM
Variables Crude Or (95% CI) P value Adjusted Or (95% CI) P value
gender




Non-Malay 0.85 (0.51–1.41) 0.53 0.86 (0.49–1.48) 0.52
BMI
Underweight/normal (1) (1)
Overweight 1.68(0.74–3.82) 0.22 1.51(0.64–3.60) 0.35
Obese 1.32 (0.59–2.95) 0.51 1.14 (0.49–2.69) 0.76
Duration of DM
< 5 years (1) (1)
≥ 5 years 2.69 (1.20–6.03) 0.02* 2.42 (1.03–5.70) 0.04*
glycemic control
Good (HbA1c ≤ 6.5%) (1) (1)
Poor (HbA1c > 6.5%) 2.16 (1.08–4.32) 0.03* 1.97 (0.95–4.10) 0.07
Diabetic Complications
Yes 1.39 (0.83–2.32) 0.21 0.94 (0.53–1.65) 0.83
No (1) (1)
*Indicate P < 0.05, (1) — reference group, adjusted for gender, ethnicity, BMI, diabetes duration, glycemic control, DM complications
ment, foot self-care advice and training to prevent the 
development of SMDC are important in patients with 
T2DM complicated by with peripheral neuropathy and 
peripheral vascular disease. There was no association 
between diabetic dermopathy and retinopathy among 
the participants of this study although diabetic der-
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mopathy is considered as a diabetic microangiopathy. 
Half of the patients with diabetic dermopathy were 
found to have retinopathy [28]. A prospective cohort 
study would yield more information on the association 
between diabetic dermopathy and retinopathy. Limita-
tion of this study is that peripheral vascular disease was 
evaluated clinically and not confirmed using arterial-
brachial pressure index (ABSI) or Doppler ultrasound 
which gives a more objective evaluation. 
Conclusions
The prevalence of cutaneous manifestation among 
T2DM in this study was high, affecting almost two 
thirds of the participants. The commonest cutaneous 
manifestation was infection and diabetic dermopathy. 
Fungus was the most common cause for infection 
presenting as onychomycosis. Risk factors for cutane-
ous manifestation of T2DM are males and duration of 
diabetes of 5 years and more. Diabetic neuropathy and 
peripheral vascular disease are risks for SMDC diabetic 
foot and trophic ulcers. Our study did not demonstrate 
an association between glycemic control and cutaneous 
manifestations of T2DM. A prospective study looking 
at glycemic control over a longer duration would be 
useful to elicit the association. T2DM patients should be 
screened early for skin manifestations especially males, 
T2DM ≥ 5 years, those with diabetic neuropathy and 
peripheral vascular disease so that management can 
be instituted early to prevent complications. 
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Table 5. risk factors for SMDC type of cutaneous manifestation of T2DM 
Variables Crude Or (95% CI) P value Adjusted Or (95% CI) P value
gender




Overweight/obesity 0.34 (0.06–1.89) 0.22 0.39 (0.04–3.74) 0.41
Duration of DM
< 5 years (1) (1)
≥ 5 years 1.08 (0.12–9.44) 0.10 0.13 (0.01–3.77) 0.24
glycemic control
Good (HbA1c ≤ 6.5%) (1) (1)
Poor (HbA1c > 6.5%) 1.43 (0.16–12.50) 0.95 1.58 (0.11–23.63) 0.74
Neuropathy
Yes 10.33 (1.83–58.15) 0.01* 23.26 (1.19–454.2) 0.04*
No (1) (1)
Nephropathy
Yes 2.73 (0.54–13.85) 0.23 1.89 (0.24–14.78) 0.55
No (1) (1)
retinopathy
Yes 5.91 (1.06–33) 0.04* 3.07 (0.34–27.72) 0.32
No (1) (1)
Peripheral vascular disease
Yes 32 (4.57–23) 0.00* 102.36 (4.01–261) 0.01*
No (1) (1)
*Indicate P < 0.05, (1) — reference group, adjusted for gender, DMI, duration of DM, glycemic control, diabetic neuropathy, nephropathy, retinopathy, and 
peripheral vascular disease
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